Research programme: NF-kappa B inhibitors - Serenex
Alternative Names: NF-kappa B inhibitors research programme - Serenex; SC103380Latest Information Update: 16 Jul 2016
At a glance
- Originator Serenex
- Class
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 28 Jan 2005 Preclinical trials in Inflammation in USA (unspecified route)